GABY CEO Margot Micallef to Speak at 2022 Emerging Growth Conference on June 8

SAN DIEGO, CA / ACCESSWIRE / June 7, 2022 / GABY Inc. (CSE:GABY)(OTCQB:GABLF) ("GABY" or the "Company"), a California consolidator of cannabis dispensaries and the parent company of San Diego's Mankind Dispensary, is pleased to announce that Founder and CEO Margot Micallef will be speaking at the upcoming Emerging Growth Conference ("EGC") to an audience of thousands of individual and institutional investors, advisors and analysts.

This live, interactive online event will give existing shareholders and the investment community an in depth look into GABY's growth and expansion strategy and provide an investment opportunity for those interested in investing in cannabis stocks before the anticipated rapid growth that will come from the passing of the Safe Banking Act, and eventual federal legalization.

"I'm excited to share GABY's mission and vision for sustainable success in the cannabis industry with attendees of the Emerging Growth Conference." Said Margot. "With investor sentiment for cannabis being hamstrung by government regulation, these conferences are some of the best opportunities for investors to learn about emerging companies, and gain an understanding of the growth opportunities that exist for a company like GABY Inc, both in the short and long term"

Margot Micallef will be presenting at 10:30 AM Eastern Time. If attendees are not able to join the event live on the day of the conference, an archived webcast will also be made available on EmergingGrowth.com. Registration is available by following this link.

About the Emerging Growth Conference

The Emerging Growth conference is an effective way for public companies to present and communicate their new products, services and other major announcements to the investment community from the convenience of their office, in a time efficient manner.

The Conference focus and coverage includes companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long term growth. Its audience includes potentially tens of thousands of Individual and Institutional investors, as well as Investment advisors and analysts.

All sessions will be conducted through video webcasts and will take place in the Eastern time zone.

ABOUT GABY

GABY Inc. is a California-focused retail consolidator and the owner of Mankind Dispensary, one of the oldest licensed dispensaries in California. Mankind Dispensary is a well-known and highly respected dispensary with deep roots in the California cannabis community operating in San Diego. GABY curates and sells a diverse portfolio of products, including its own proprietary brands, Kind Republic™ Dank Space™ and Lulu's™ through Mankind, A pioneer in the industry with a strong management team with experience in retail, consolidation, and cannabis, GABY is poised to grow its retail operations both organically and through acquisition.

GABY's common shares trade on the Canadian Securities Exchange ("CSE") under the symbol "GABY" and on the OTCQB under the symbol "GABLF". For more information on GABY, visit www.GABYInc.com or the Company's SEDAR profile at www.sedar.com

For further inquiries, please contact:

General
Margot Micallef, Founder & CEO or Investor Relations at IR@GABYinc.com

Media
Senior Communications Manager
Charlie Rohlfs
(631) 579-0858
charlie@gabyinc.com

Disclaimer and Forward-Looking Information

The CSE does not accept responsibility for the adequacy or accuracy of this release. Certain information set forth in this news release may contain forward-looking statements that involve substantial known and unknown risks and uncertainties, certain of which are beyond the control of the Company. Forward-looking statements are frequently characterized by words such as "plan", "continue", "expect", "project", "intend", "believe", "anticipate", "estimate", "may", "will", "potential", "proposed" and other similar words, or statements that certain events or conditions "may" or "will" occur. These statements are only predictions. Readers are cautioned that the assumptions used in the preparation of such information, although considered reasonable at the time of preparation, may prove to be imprecise and, as such, undue reliance should not be placed on forward-looking statements. Forward-looking statements include, but are not limited to, the future price of the Company's securities, and the Company's future business strategy, including its plans to expand organically and through future acquisitions. Although GABY believes that the expectations and assumptions on which such forward-looking statements and information are based are reasonable, undue reliance should not be placed on the forward-looking statements and information because GABY can give no assurance that they will prove to be correct. By its nature, such forward-looking information is subject to various risks and uncertainties, which could cause the actual results and expectations to differ materially from the anticipated results or expectations expressed. Without limitation, these risks and uncertainties include: the state of capital markets; the severity of the COVID-19 pandemic; risks associated with the cannabis industry in general; failure to benefit from partnerships or successfully integrate acquisitions; actions and initiatives of federal, state and provincial governments and changes to government policies and the execution and impact of these actions, initiatives and policies; the size of the medical-use and adult-use cannabis market; competition from other industry participants; adverse U.S., Canadian and global economic conditions; failure to comply with certain regulations; and departure of key management personnel or inability to attract and retain talent. GABY undertakes no obligation to update publicly or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by law.

Certain information contained herein has been prepared by third-party sources. Such information has not been independently audited or verified by the Company. The Company has used its best efforts to ensure the accuracy and completeness of the information presented. The information contained in this release from NCM's report is qualified in its entirety by the full NCM report available at:

www.channelchek.com/news-channel/GABY_Inc.__GABLF____GABY_Inc._Focused_on_California_Cannabis_Consolidation

The information contained in this release does not purport to contain all the information that may be necessary or desirable to fully and accurately evaluate an investment in the Company and is not to be considered as a recommendation by the Company that any person make an investment in the Company's securities.

Each of Mankind Dispensary and Wild West Industries are subsidiaries of GABY and hold a cannabis license in the State of California. Readers are cautioned that unlike in Canada which has Federal 032320-F legislation uniformly governing the cultivation, distribution, sale and possession of medical cannabis under the Cannabis Act (Federal), in the United States ("U.S."), cannabis is largely regulated at the State level. Cannabis is legal in the State of California; however, cannabis remains illegal under U.S. federal laws. Notwithstanding the permissive regulatory environment of cannabis at the State level, cannabis continues to be categorized as a controlled substance under the Controlled Substances Act in the U.S. and as such, cannabis-related practices or activities, including without limitation, the manufacture, importation, possession, use or distribution of cannabis are illegal under U.S. federal law. To the knowledge of the Company, the businesses operated by each of GABY's subsidiaries are conducted in a manner consistent with the State law of California, as applicable, and are in compliance with regulatory and licensing requirements applicable in the State of California, respectively. However, readers should be aware that strict compliance with State laws with respect to cannabis will neither absolve GABY, or its subsidiary of liability under U.S. federal law, nor will it provide a defense to any federal proceeding in the U.S. which could be brought against any of GABY, or its subsidiary. Any such proceedings brought against GABY, or its subsidiary may materially adversely affect the Company's operations and financial performance generally in the U.S. market specifically.

SOURCE: GABY Inc.